Where is Syapse located?

Syapse is headquartered in San Francisco, United States. It is registered at San Francisco,California.

How many employees does Syapse have?

As of Feb 12, 2025, the latest employee count at Syapse is 52.

Is Syapse a funded company?

Syapse is a funded company, having raised a total of $223M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of Syapse?

Syapse's latest funding was a $***** Series E round on Jul 07, 2022, with participation from 7 investors. Its primary sector is Healthcare IT. In United States, the Healthcare IT sector has seen $3.97B in funding in 2026 to date.

Where does Syapse rank among its competitors?

Syapse ranks 3rd amongst 16 active competitors, of which 4 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was VieCure, which secured $43M in Jan, 2026.

Who are the top competitors of Syapse?

Syapse's top competitors include VieCure, BostonGene and Oncospace. Among them, VieCure secured the most recent funding round in January, 2026.

Syapse - 2026 Company Profile, Team, Funding & Competitors

Syapse is an acquired company based in San Francisco (United States), founded in 2008 by Jonathan Hirsch, Tony Loeser and Glenn Winokur. It operates as a Developer of precision medicine for the treatment of cancer. Syapse has raised $223M in funding from investors like Safeguard Scientifics, Ascension Ventures and Medidata. The company has 16 active competitors, including 4 funded and 2 that have exited. Its top competitors include companies like VieCure, BostonGene and Oncospace.

Company Details

Developer of precision medicine for the treatment of cancer. The company's platform uses molecular profiling for the analysis of complex genomic data of the patient with cancer.

Website: syapse.com
Social
Email ID: *****@syapse.com
Registered Address: San Francisco,California

Key Metrics

Founded Year

2008

Location

San Francisco, United States

Stage

Acquired

Total Funding

$223M in 9 rounds

Latest Funding Round

Series E, Jul 07, 2022, $*****

Investors

Safeguard Scientifics & 15 more

Ranked

3^rd among 16 active competitors

Employee Count

52 as on Feb 12, 2025

Similar Companies

VieCure & 20 more

Exit Details

Acquired by N-Power Medicine (Jan 13, 2025)

View Syapse's full profile

Syapse is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SYAPSE, INC. CIN: 263457459 , United States, Active	Dec 31, 1999	-	177 (As on Dec 31, 2022)	-

Syapse got acquired by N-Power Medicine on Jan 13, 2025.

Click here to take a look at Syapse's acquisition in detail

Syapse has raised a total funding of $223M over 9 rounds. Its latest funding round was a Series E round on Jul 07, 2022 for $*****. 7 investors participated in its latest round. Syapse has 16 institutional investors.

Here is the list of recent funding rounds of Syapse:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 07, 2022	5493843	Series E	3303092	3171710	3486589	1009760
Feb 02, 2021	3281127	Series E	4894579	8616420	4697486	Northpond Ventures
May 28, 2020	7341376	Series E	3458226	7966314	Revelation Partners	Intermountain Ventures & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Syapse's funding rounds and investors

The founders of Syapse are Jonathan Hirsch, Tony Loeser and Glenn Winokur.

Here are the details of Syapse's key team members:

Jonathan Hirsch: Founder of Syapse and founder of 2 other companies, Quadrotian and Synapticure. They are also an angel investor in 2 startups.
Tony Loeser: Co-Founder & CTO of Syapse.
Contact Info: 1 email address
Glenn Winokur: Former Co-Founder of Syapse and founder of 1 other company.

View details of Syapse's Founder profiles and Board Members

Syapse's employee count trend

Syapse has 52 employees as of Feb 25. Here is Syapse's employee count trend over the years:

Uncover Syapse's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Syapse include VieCure, BostonGene and Oncospace. Here is the list of Top 10 competitors of Syapse, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	VieCure 2015, Greenwood Village (United States), Series C	AI-based platform for generating oncology treatment plans	$113M	Northpond Ventures, Durable Capital Partners ... & 2 others	63/100
2nd	BostonGene 2015, Waltham (United States), Series B	Developer of cloud-based information and analytics platform to treat cancer	$200M	NEC, Japan Industrial Partners & 1 others	57/100
3rd	Syapse 2008, San Francisco (United States), Acquired	Developer of precision medicine for the treatment of cancer	$223M	Amgen Business Development, Merck Global Health Innovation Fund ... & 14 others	55/100
4th	Oncospace 2018, Baltimore (United States), Acquired	Provider of healthcare solutions focused on cancer patients	$900K	NIH, America’s Seed Fund	39/100
5th	OncoRx Insights 2022, Boulder (United States), Unfunded	Provider of radical new insights and solutions for oncologists and patients in the healthcare industry	-	-	28/100
6th	Melatech 2018, Copenhagen (Denmark), Seed	AI-based patient treatment management tool for providers	$574K	Accelerace & 2 others	28/100
7th	PersonaDx 2022, Chicago (United States), Unfunded	Provider of a platform for diagnosis and treatment of cancer through blood-based biomarker tests	-	-	25/100
8th	Curenetics London (United Kingdom), Unfunded	Cloud and AI-based cancer care planning platform for professionals	-	-	24/100
9th	Iakan Health 2019, Valencia (Spain), Funding Raised	Provider of an AI-based decision support platform for personalized cancer treatment	-	Lanzadera	23/100
10th	Myka Labs 2021, San Francisco (United States), Funding Raised	Provider of an AI-based integrated solutions for interventional oncology	-	Mission BioCapital	22/100